1. Illumina and CENTOGENE: Using NIPT to Screen for the Most Common Fetal Chromosomal Abnormalities

Illumina and CENTOGENE: Using NIPT to Screen for the Most Common Fetal Chromosomal Abnormalities

Prof. Peter Bauer, MD 1 Kristin Dalton 2
1 CENTOGENE AG 2 Illumina
July 24, 2017

If you can´t see the webinar on Youtube, click here to watch it.

Using NIPT to screen for the most common fetal chromosomal abnormalities

Illumina VeriSeq™ NIPT Solution*

CENTOGENE has a new addition to its prenatal portfolio: CentoNIPT®, its innovative non-invasive prenatal testing that provides a fast and accurate screening for the most common prenatal chromosomal abnormalities (Trisomy 21, Trisomy 18, Trisomy 13 and sex chromosomes).

CentoNIPT® combines next generation sequencing with integrated measurement of fetal fraction, even when the fetal fraction is less than 4%. Based on the Illumina Verifi Prenatal Test & VeriSeq™ NIPT solution, CentoNIPT® promises the lowest test failure rate among NIPT technologies on market (30 – 50 % lower).

Webinar content

  • Introduction to NIPT and difference with classic prenatal testing
  • Methodology/technology
  • Pre-test and post-test counseling considerations
  • Report example – CENTOGENE base

Notation: *Sample Preparation and analysis software are CE-IVD marked.

Our speakers

Kristin Dalton
, Genetic Counselor at Illumina

Kristin Dalton, a licensed and certified Genetic Counselor, joined Illumina's Reproductive and Genetics Health team in June 2015. She is involved in several projects and educational activities related to noninvasive prenatal testing and she provides support for Illumina's partners in Europe, the Middle East, and Africa. Before joining Illumina, Kristin provided genetic counseling to patients and families at Baystate Medical Center in Massachusetts, USA for 13 years and specialized in reproductive genetic counseling.

Prof. Peter Bauer
, Chief Scientific Officer at CENTOGENE

Peter Bauer received his board certification in Human Genetics in 2006 and headed the molecular diagnostic laboratory at the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. Moreover, he is Vice President of the German Society of Neurogenetics (DGNG). Peter has authored more than 140 publications in neurogenetics, oncogenetics, cardiogenetics and sequencing technology and is leading author of the ‘Guidelines for diagnostic next-generation sequencing’ (Eur. J. Hum. Genet. 2016).